Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZymeworksZYME +0.76%63 Cash Ratio is 5.73 as of Jun. 2026, which is 13% above its 10-year median of 5.06. GuruFocus rates ZYME with a GF Score™ of 63/100 and a GF Value™ of $17.81 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,377 Biotechnology companies, Zymeworks ranks better than 67.61% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Zymeworks Cash Ratio Related Terms
Zymeworks Cash Ratio Historical Data
* Premium members only.
The historical data trend for Zymeworks's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zymeworks's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Zymeworks's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (ZYME) has a Cash Ratio of 5.73 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zymeworks and its competitors. This is 13% above median its historical median of 5.06. Over the past decade, Zymeworks' Cash Ratio has ranged from 1.29 to 10.23. According to the industry distribution chart, Zymeworks ranks #446 out of 1377 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Zymeworks' Cash Ratio too high?
Zymeworks' current Cash Ratio of 5.73 is 13% above median its 10-year median of 5.06. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 10.23. The Biotechnology industry median Cash Ratio is 2.96. Zymeworks' value of 5.73 is 93.6% above this industry median. Based on the distribution chart, Zymeworks ranks #446 out of 1377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zymeworks has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Cash Ratio compare to MPLT and SRPT?
According to the Biotechnology industry distribution chart, Zymeworks ranks #446 out of 1377 companies for Cash Ratio. This puts Zymeworks in the upper half of its industry. The industry median Cash Ratio is 2.96. Zymeworks' value of 5.73 is 93.6% above this benchmark. Historically, Zymeworks' own Cash Ratio has ranged from 1.29 to 10.23 over the past decade. While the company's 10-year median is 5.06 vs. the industry median of 2.96, Zymeworks has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zymeworks's current Cash Ratio of 5.73 is 93.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zymeworks and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zymeworks's current Cash Ratio is 5.73, which is 13% above median its own 10-year median of 5.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.81, compared to a current price of $25.33 — trading 42.2% above its estimated fair value. The current Cash Ratio is 5.73, which is 13% above median its 10-year median of 5.06 and 93.6% above the Biotechnology industry median of 2.96. Zymeworks' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Zymeworks (ZYME), the current Cash Ratio is 5.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zymeworks (ZYME) Overvalued in 2026?
Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued.
The current stock price of $25.33 is trading 42.2% above its estimated GF Value™ of $17.81.
GuruFocus considers Zymeworks to be Significantly Overvalued.
Key valuation signals for ZYME:
Cash Ratio: 5.73 (13% above median its 10-year median of 5.06)
GF Value™: $17.81 vs. price of $25.33 (42.2% above fair value)
Industry Position: 93.6% above the Biotechnology median (#446 of 1377)
No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
63GF Score
Get the complete analysis for ZYME
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYME has been successfully added to your 
